ESR1 mutations are relatively rare in newly diagnosed, treatment naïve breast cancer (less than 7% mutation rates in primary tumor), but appear to be frequently acquired in hormone-resistant MBC (15% - 55%). This evidence concerns the gene ESR1 and breast carcinoma.